Hunter David J, Hellio Le Graverand-Gastineau Marie-Pierre
Division of Research, New England Baptist Hospital, 125 Parker Hill Ave., Boston, MA 02120, USA.
Rheum Dis Clin North Am. 2008 Aug;34(3):789-802. doi: 10.1016/j.rdc.2008.05.003.
This article describes what structure modification is, explains the distinctions among preventing, retarding, stopping, and reversing disease, and suggests approaches that might be clinically meaningful. It discusses whether any evidence suggests it is possible to modify disease and whether the current focus on cartilage is appropriate. It considers the methodologic approaches and the obstacles to demonstrating efficacy of these agents in clinical trials. The authors hope that at the end of this narrative review the reader will appreciate the complexities of this rapidly evolving field and of the development of disease-modifying drugs for osteoarthritis drugs.
本文描述了结构改变是什么，解释了预防、延缓、阻止和逆转疾病之间的区别，并提出了可能具有临床意义的方法。它讨论了是否有证据表明可以改变疾病，以及目前对软骨的关注是否恰当。它考虑了方法学途径以及在临床试验中证明这些药物疗效的障碍。作者希望在这篇叙述性综述结束时，读者能认识到这个快速发展的领域以及骨关节炎疾病修饰药物开发的复杂性。
